391
Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
Condition(s):Multiple Myeloma; Plasma Cell LeukemiaLast Updated:April 4, 2016Terminated
Stage III Multiple Myeloma: 436 Clinical Trials, Page 40 of 44
Hide Studies Not Open or Pending
392
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Condition(s):Multiple MyelomaLast Updated:February 22, 2016Completed
393
A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
Condition(s):Light Chain (AL) Amyloidosis, Stage 3BLast Updated:March 14, 2023Active, not recruiting
394
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Condition(s):Light Chain Deposition Disease; Smoldering Multiple MyelomaLast Updated:September 13, 2023Active, not recruiting
395
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
Condition(s):Multiple Myeloma and Plasma Cell NeoplasmLast Updated:July 4, 2012Completed
396
Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.
Condition(s):Multiple MyelomaLast Updated:June 14, 2022Recruiting
397
UARK 2013-13, Total Therapy 4B – Formerly 2008-01 – A Phase III Trial for Low Risk Myeloma
Condition(s):Multiple MyelomaLast Updated:August 9, 2023Active, not recruiting
398
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Condition(s):Multiple Myeloma Stage ILast Updated:April 11, 2012Terminated
399
Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma (MYELOMEFRAGIQUANTI)
Condition(s):Multiple Myeloma; Vertebral FractureLast Updated:November 6, 2020Unknown status
400
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma
Condition(s):High-risk Smoldering Multiple MyelomaLast Updated:January 27, 2020Completed